Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/172759
Title: Overview of pneumococcal serotypes and genotypes causing diseases in patients with chronic obstructive pulmonary disease in a Spanish hospital between 2013 and 2016
Author: Shoji, Hisashi
Vázquez Sánchez, Daniel A.
González Díaz, Aida
Cubero, Meritxell
Tubau, Fe
Santos Pérez, Salud
García Somoza, Dolores
Liñares Louzao, Josefina
Yuste, José
Martí, Sara
Ardanuy Tisaire, María Carmen
Keywords: Malalties pulmonars obstructives cròniques
Pneumococs
Vacunes
Hospitals
Chronic obstructive pulmonary diseases
Streptococcus pneumonia
Vaccines
Hospitals
Issue Date: 2018
Publisher: Dove Medical Press
Abstract: Background: Streptococcus pneumoniae is an important pathogen in chronic obstructive pulmonary disease (COPD). We aimed at showing the recent changes in the epidemiology of pneumococcal diseases in patients with COPD, especially after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13). Methods: From 2013 to 2016, strains causing invasive pneumococcal disease (IPD), non-bacteremic pneumococcal pneumonia (non-BPP), and acute exacerbation of COPD (AE-COPD) were prospectively included. Antimicrobial susceptibility testing, serotyping, and genotyping were analyzed. Results: We collected 345 pneumococci from 286 COPD patients (57 IPD, 78 non-BPP, and 210 AE-COPD). The most frequent serotypes were serotypes 3 (14.0%), 8 (14.0%), and 12F (8.8%) in IPD; serotypes 3 (16.7%), 11A (9%), 9L/N (7.7%), and 23A (7.7%) in non-BPP; and serotypes 11A (11%), nontypeable (11%), and 6C (10%) in AE-COPD. Resistance rates were highest among AE-COPD strains. Penicillin resistance was associated with serotypes 11A (CC156) and 19A (CC320 and CC230). Compared with previous studies, fluoroquinolone resistance in AE-COPD increased (9.5%), PCV13 serotypes decreased (31.6%, 26.9%, and 16.7% for IPD, non-BPP, and AE-COPD, respectively), and serotype 11A-CC156 in AE-COPD and serotype 8 in IPD increased. Conclusion: The epidemiology of pneumococcal disease in COPD changed after the introduction of PCV13 in children. Increases in the highly invasive serotype 8 among patients with IPD and in serotype 11A-CC156 among patients with AE-COPD could compromise the ability of current PCVs to prevent diseases. Vaccines with a greater coverage could improve the benefits of adult vaccination.
Note: Reproducció del document publicat a: https://doi.org/10.2147/IDR.S165093
It is part of: Infection and Drug Resistance, 2018, vol. 11, p. 1387-1400
URI: http://hdl.handle.net/2445/172759
Related resource: https://doi.org/10.2147/IDR.S165093
ISSN: 1178-6973
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Medicina)
Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
680152.pdf754.12 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons